Cocrystal Pharma (COCP) Net Equity Issued and Repurchased (2012 - 2021)

Cocrystal Pharma (COCP) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $2.1 million in Q1 2021.

• For the quarter ending Q1 2021, Net Equity Issued and Repurchased fell 87.52% year-over-year to $2.1 million; the trailing twelve-month figure through Sep 2023 stood at $2.1 million (changed N/A YoY), and the FY2025 full-year result was $154000.0, changed N/A from the prior year.
• Net Equity Issued and Repurchased slipped to $2.1 million in Q1 2021, from $3.6 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $16.6 million in Q1 2020 to a low of -$744000.0 in Q2 2018.
• A 4-year average of $4.7 million and a median of $3.2 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased surged 322.76% in 2020 and slumped 87.52% in 2021, its largest moves.
• Tracing COCP's Net Equity Issued and Repurchased over 4 years: stood at -$744000.0 in 2018, then surged by 464.25% to $2.7 million in 2019, then surged by 33.65% to $3.6 million in 2020, then plunged by 42.79% to $2.1 million in 2021.
• Business Quant data shows COCP's Net Equity Issued and Repurchased at $2.1 million in Q1 2021, $3.6 million in Q4 2020, and $16.6 million in Q1 2020.